Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the critical federal funding at risk and what this ...

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Researchers have identified a range of genetic alterations that may lead to resistance to KRAS G12C inhibitors in patients ...

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved ...